Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to manage type 2 diabetes and, since 2021, for weight loss in individuals with obesity or weight-related comorbidities. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.